This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abi-Dargham, A. Articles by Moore, H. Search for Related Content PubMed PubMed Citation Articles by Abi-Dargham, A. Articles by Moore, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOPAMINE Medline Plus Health Information Schizophrenia Social Bookmarking                   What's this?

Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia

Departments of Psychiatry and Radiology, Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute, New York, aa324{at}columbia.edu

Holly Moore

Departments of Psychiatry, Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute, New York

The current view on the dopamine (DA) hypothesis of schizophrenia postulates a cortical/subcortical imbalance: subcortical mesolimbic DA projections might be hyperactive, resulting in hyperstimulation of D₂receptors and positive symptoms, whereas mesocortical DA projections to the prefrontal cortex might be hypoactive, resulting in hypostimulation of D₁ receptors, negative symptoms, and cognitive impairment. Although the subcortical abnormalities are relatively well established now, the evidence for cortical hypodopaminergia is just emerging. This article will review current evidence for prefrontal hypodopaminergia in schizophrenia, with special emphasis on positron emission tomography (PET) studies measuring cortical D₁ receptors in schizophrenia. The presentation of the clinical data will be introduced by a brief overview of the function of prefrontal DA systems, both at the cellular and cognitive level. The impact of antipsychotic drugs on prefrontal DA function will also be reviewed. We will conclude with the formulation of several models of altered prefrontal DA transmission at D₁ receptors in schizophrenia.

Key Words: Schizophrenia • DLPFC • D1 receptors • Dopamine • PET

The Neuroscientist, Vol. 9, No. 5, 404-416 (2003)
DOI: 10.1177/1073858403252674


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, July 1, 2009; 35(4): 789 - 797. [Abstract] [Full Text] [PDF]

				J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]

				J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]

				L. Chen, J. D. Bohanick, M. Nishihara, J. K. Seamans, and C. R. Yang Dopamine D1/5 Receptor-Mediated Long-Term Potentiation of Intrinsic Excitability in Rat Prefrontal Cortical Neurons: Ca2+-Dependent Intracellular Signaling J Neurophysiol, March 1, 2007; 97(3): 2448 - 2464. [Abstract] [Full Text] [PDF]

				J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry, November 1, 2006; 63(11): 1189 - 1197. [Abstract] [Full Text] [PDF]

				M. Ito, T. Nagai, H. Kamei, N. Nakamichi, T. Nabeshima, K. Takuma, and K. Yamada Involvement of Tissue Plasminogen Activator-Plasmin System in Depolarization-Evoked Dopamine Release in the Nucleus Accumbens of Mice Mol. Pharmacol., November 1, 2006; 70(5): 1720 - 1725. [Abstract] [Full Text] [PDF]

				J. Hirvonen, T. G.M. van Erp, J. Huttunen, S. Aalto, K. Nagren, M. Huttunen, J. Lonnqvist, J. Kaprio, T. D. Cannon, and J. Hietala Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia Am J Psychiatry, October 1, 2006; 163(10): 1747 - 1753. [Abstract] [Full Text] [PDF]

				M. V. Madsen, L. Peacock, T. Werge, and M. B. Andersen Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebusmonkeys J Psychopharmacol, September 1, 2006; 20(5): 622 - 628. [Abstract] [PDF]

				S. Natesan, K. A. Svensson, G. E. Reckless, J. N. Nobrega, K. B. L. Barlow, A. M. Johansson, and S. Kapur The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 810 - 818. [Abstract] [Full Text] [PDF]

				C. R. Yang and L. Chen Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment Neuroscientist, October 1, 2005; 11(5): 452 - 470. [Abstract] [PDF]